IRIS Accounts Production v24.2.0.383 Other Company accounts True false Pounds 1.1.23 31.12.23 31.12.23 FY FRS 102 Independent examiner Small companies regime for accounts Full Charities SORP true true true true false true false true 1 1 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh050176622022-12-31050176622023-12-31050176622023-01-012023-12-31050176622021-12-31050176622022-01-012022-12-31050176622022-12-3105017662ns0:CharitableCompanyLimitedByGuarantee2023-01-012023-12-3105017662ns15:PoundSterling2023-01-012023-12-3105017662ns11:FRS1022023-01-012023-12-3105017662ns11:IndependentExaminationCharity2023-01-012023-12-3105017662ns11:SmallCompaniesRegimeForAccounts2023-01-012023-12-3105017662ns11:FullAccounts2023-01-012023-12-3105017662ns11:CharitiesSORP2023-01-012023-12-3105017662ns16:EnglandWales2023-01-012023-12-3105017662ns11:RegisteredOffice2023-01-012023-12-3105017662ns0:Trustee22023-01-012023-12-3105017662ns0:Trustee32023-01-012023-12-3105017662ns0:Trustee42023-01-012023-12-3105017662ns0:Trustee52023-01-012023-12-3105017662ns0:Trustee62023-01-012023-12-3105017662ns0:Trustee72023-01-012023-12-3105017662ns0:Trustee82023-01-012023-12-3105017662ns0:Trustee92023-01-012023-12-3105017662ns0:Trustee102023-01-012023-12-3105017662ns0:Trustee12023-01-012023-12-3105017662ns0:Trustee112023-01-012023-12-3105017662ns0:Trustee122023-01-012023-12-3105017662ns0:Trustee132023-01-012023-12-3105017662ns0:Trustee142023-01-012023-12-3105017662ns0:Trustee152023-01-012023-12-3105017662ns0:Trustee162023-01-012023-12-3105017662ns0:Trustee172023-01-012023-12-3105017662ns0:Trustee182023-01-012023-12-3105017662ns0:TotalUnrestrictedFunds2023-01-012023-12-3105017662ns0:TotalRestrictedIncomeFunds2023-01-012023-12-3105017662ns0:TotalUnrestrictedFunds2022-12-3105017662ns0:TotalRestrictedIncomeFunds2022-12-3105017662ns0:TotalUnrestrictedFunds2023-12-3105017662ns0:TotalRestrictedIncomeFunds2023-12-3105017662ns0:TotalUnrestrictedFundsns10:WithinOneYear2023-12-3105017662ns0:TotalRestrictedIncomeFundsns10:WithinOneYear2023-12-3105017662ns10:WithinOneYear2023-12-3105017662ns10:WithinOneYear2022-12-3105017662ns0:TotalUnrestrictedFundsns10:AfterOneYear2023-12-3105017662ns10:AfterOneYearns0:TotalRestrictedIncomeFunds2023-12-3105017662ns10:AfterOneYear2023-12-3105017662ns10:AfterOneYear2022-12-310501766222023-01-012023-12-310501766232023-01-012023-12-310501766212023-01-012023-12-3105017662ns0:TotalUnrestrictedFunds2022-01-012022-12-3105017662ns0:TotalRestrictedIncomeFunds2022-01-012022-12-3105017662ns10:CostValuationns10:UnlistedNon-exchangeTraded2022-12-3105017662ns10:WithinOneYear2023-01-012023-12-31
REGISTERED COMPANY NUMBER: 05017662 (England and Wales)
REGISTERED CHARITY NUMBER: 1106320














Report of the Trustees and

Unaudited Financial Statements for the Year Ended 31 December 2023

for

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER
(A COMPANY LIMITED BY GUARANTEE)

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER






Contents of the Financial Statements
for the year ended 31 DECEMBER 2023




Page

Report of the Trustees 1 to 5

Independent Examiner's Report 6

Statement of Financial Activities 7

Balance Sheet 8 to 9

Cash Flow Statement 10

Notes to the Cash Flow Statement 11

Notes to the Financial Statements 12 to 18

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER (REGISTERED NUMBER: 05017662)

Report of the Trustees
for the year ended 31 DECEMBER 2023


The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity's governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland published on 16 July 2014 (as amended by Update Bulletin 1 published on 2 February 2016).

OBJECTIVES AND ACTIVITIES
Objectives and aims
The objectives of the company, as set out in the Memorandum of Association as amended by Special Resolution, are to advance education and awareness in liver disease and disorder, by the provision or the facilitation of research directed towards the development and evaluation of treatment of such disease and disorders. The trustees confirm that they have referred to the guidance contained in the Charity Commission's guidance on public benefit when reviewing the association's aims and objectives and in planning future activities.

The Trustees carry out these objects by:


- Having educational meetings for medical professionals to attend to further their knowledge and advance education, awareness and research into liver disease.

- Supporting special interest groups to further education of specific areas of liver disease.

To assess success in the reporting period, BASL aim to maintain and increase membership, provide educational events; predominantly the Annual Scientific Meeting. To maintain sufficient funds to allow these activities to take place.

Contribution
The contribution of each member is limited to £1 in the event of a dissolution of the Company.


THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER (REGISTERED NUMBER: 05017662)

Report of the Trustees
for the year ended 31 DECEMBER 2023

ACHIEVEMENT AND PERFORMANCE
Charitable activities
BASL Annual Meeting (incorporating the annual BTLG and BLNA meeting)
The 2023 BASL Annual meeting was held at the DoubleTree Metropole in Brighton and proved to be a great success providing interaction and learning opportunities. There were 639 delegates across all three meetings which made an excellent surplus. The Sheila Sherlock prize went to Dr Kushala Abeysekera and Dr Oliver Tavabie received the Andrew Burroughs Young Investigator award.

BASL Schools
BASL Schools are small group meetings provided free of charge to trainee members in Gastroenterology and Hepatology that deliver structured education and interaction with experts in the field. These help the charity to meet its objectives by committing to improving clinical education and training for tomorrow's Hepatology Consultants, Trainees interested in transplantation and anaesthesia.
These were held as 6 interactive Webinars. These proved to be a great success and feedback was excellent.

BASL Xtra
This is an online educational conference and was the second one to be held. This a multi-professional, topic focused educational online event. Attendance and surplus were excellent and the decision was made to continue to hold this event annually.

BASL Introduction to Hepatology Day
The meeting was held in Birmingham. This was deemed to be a great success and provided a small surplus.

BVHG Meetings
Two meetings were held in 2023 due to the 2022 meeting being delayed until January 2023. These meetings were very popular and provided an excellent surplus.

BASL Basic Science Retreat
This was held in London and any shortfall was covered by the Institute of Hepatology, who organised the event on behalf of BASL. This was very popular and well attended.

Special Interest Groups
BASL provides ongoing administrative support to a number of established Special Interest Groups (SIGs) whose remit is to promote and encourage collaborative research and clinical trials in liver disease.

HCC-UK Annual Meeting
This was held at the Royal College of Physicians in Edinburgh. This was very well attended and made an excellent .
surplus

CCA-UK Annual Meeting
This was held in Nottingham and made a significant deficit. Changes were made to future format for this meeting to prevent more deficit.

BAAL
This was the first meeting for this newly formed group, held in Birmingham. Costs were covered and a small surplus was made.

BHPG Educational Meeting
Meetings were held in February and November in 2023 and a good surplus was made due to good sponsorship being achieved.

Secretariat
Secretariat services were provided by Executive Business Support Ltd.


THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER (REGISTERED NUMBER: 05017662)

Report of the Trustees
for the year ended 31 DECEMBER 2023

To ensure a balanced picture of the charity's progress against its objectives, sufficient funds are maintained to allow the Desired educational events held to continue to take place.

The key performance indicators to explain outputs achieved by activities are the level and numbers of members increasing, as well as maintaining delegate members at educational events.

FINANCIAL REVIEW
Financial position
Detailed finance reports are produced for the Trustees for every governing board meeting. The Trustees aim to achieve a Surplus or Breakeven for every educational meeting. The results for the year are shown on page 16. The trustees aim to hold sufficient reserves to support key meetings in the event of potential shortfalls in income. The membership and subscriptions database has been updated and clarified and the charity currently has 1,624 (2022: 1,423) active members. The BASL website continued to provide a good platform for providing news and information as well as serving as an interactive communications and education hub for members.

The charity managed to achieve income of £533,539 (2022: £397,892) during the year.

Cash reserves have been stable at £261,210 (2022: £206,737) due to the charity continuing to hold events on a virtual basis, as well as face to face, resulting in lower costs as a result and in addition, increasing membership fees.

The trustees believe that the charity has sufficient reserves to continue and hopes to achieve a greater surplus in 2024 with the aim of holding events on a face to face basis, as well as some on a virtual basis. The charity always hopes to retain reserves in unrestricted funds to cover 24 months operational costs and at the end of the accounting period, these had decreased to £173,615 (2022: £125,001). It is hoped that reserves will return to former levels over the next two years and be able to cover 24 months of operational costs during the 2024 and 2025 accounting periods.

Significant events that have affected financial performance and financial position during the period, include an increase in face to face meetings held, following more virtual events during 2020 - 2022 due to Covid. This resulted in an increase in costs to hold meetings as well as increased sponsorship and delegate income. Close attention is made to ensure all events held make a surplus or at the very least cost neutral. Factors likely to affect future financial performance or position are the advancement in medical science resulting in an increase in education of the members and potential increase in sponsorship from Pharmaceutical companies to promote new treatments. Principal funding sources are the membership income as well as sponsorship from Pharmaceutical companies and delegate income from events.

Reserves policy
Reserves are needed as sponsorship by Pharmaceutical companies of educational events, which are one of the key objectives of BASL, can drop suddenly depending on the current focus of the Pharmaceutical Companies. As stated in the Articles of Association: The Association will aim to retain sufficient capital funds in reserve to permit it to conduct its activities as defined by the Governing Board for a period of two years in the absence of any income over this period.

FUTURE DEVELOPMENTS
The Trustees aim to continue to provide educational meetings and other member benefits in accordance with the objectives of the Charity. The experience of the pandemic has resulted in the ability to run meetings on a virtual basis to ensure events still take place, making meetings accessible to members and meaning external risk factors are more manageable.

STRUCTURE, GOVERNANCE AND MANAGEMENT
Governing document
The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.


THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER (REGISTERED NUMBER: 05017662)

Report of the Trustees
for the year ended 31 DECEMBER 2023


STRUCTURE, GOVERNANCE AND MANAGEMENT
Induction and training of new trustees
Newly elected trustees attend quarterly meetings with the Chairperson and the governing board to observe the provision of services to members. They are also given guidance which include an outline of their role and a handover from the outgoing Trustee.

The charity makes decisions through it's governing board. Policies and procedures for induction and training of trustees is supported by the current and outgoing Trustees.

REFERENCE AND ADMINISTRATIVE DETAILS
Registered Company number
05017662 (England and Wales)

Registered Charity number
1106320

Registered office
Executive Business Support
Davidson Road
Lichfield
Staffordshire
WS14 9DZ

Trustees
Dr T J S Cross Consultant Hepatologist (appointed 22.9.23)
Professor B R Davidson Hepatobiliary and Transplant Consultant (resigned 22.9.23)
Dr T J Kendall Senior Clinical Fellow In Pathology
Dr I A C Rowe University Clinical Academic Fellow
Dr V Snowdon Consultant Hepatologist
Ms M B Clayton Lecturer In Liver Care
Dr M A Aldersley Consultant Hepatologist (resigned 1.2.23)
Dr K J Simpson Consultant Physician and Senior Lecturer (resigned 1.10.23)
Professor M E Cramp Consultant Hepatologist
Dr A M Elsharkawy Consultant Hepatologist
Dr R Jones Consultant Hepatologist (resigned 22.9.23)
Dr K Drysale Hepatolgy Registrar Clinical Research (resigned 31.1.23)
Professor R Mookerjee Professor of Translational Hepatology
Dr M Allison Consultant Hepatologist
Dr S Chokshi Acting Director & Chief Scientific Offic
Dr O A A Elshaarawy (appointed 18.5.23)
Professor P Kennedy Consultant Hepatologist and Gastroentero (appointed 30.1.23)
Mr J A Richard Doctor (appointed 31.10.23)

Independent Examiner
Carl Elsby ACA
Elsby & Co (Sywell) Ltd
Chartered Accountants
155 Wellingborough Road
Rushden
Northamptonshire
NN10 9TB


THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER (REGISTERED NUMBER: 05017662)

Report of the Trustees
for the year ended 31 DECEMBER 2023

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by order of the board of trustees on 19 September 2024 and signed on its behalf by:





Dr A M Elsharkawy - Trustee

Independent Examiner's Report to the Trustees of
The British Association for the Study of
the Liver

Independent examiner's report to the trustees of The British Association for the Study of the Liver ('the Company')
I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2023.

Responsibilities and basis of report
As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement
Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.








Carl Elsby ACA

Elsby & Co (Sywell) Ltd
Chartered Accountants
155 Wellingborough Road
Rushden
Northamptonshire
NN10 9TB

19 September 2024

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Statement of Financial Activities
for the year ended 31 DECEMBER 2023

2023 2022
Unrestricted Restricted Total Total
funds funds funds funds
Notes £    £    £    £   
INCOME AND ENDOWMENTS FROM
Membership subscriptions 3 116,383 - 116,383 99,160

Conference fees & sponsorship income 4 413,049 - 413,049 297,904
Interest receivable 5 4,107 - 4,107 828
Total 533,539 - 533,539 397,892

EXPENDITURE ON
Conference costs
Direct conference costs 6 287,534 - 287,534 206,048
Other associated conference costs 7 189,113 - 189,113 197,398
476,647 - 476,647 403,446


Other 9,014 - 9,014 13,476
Total 485,661 - 485,661 416,922

NET INCOME/(EXPENDITURE) 47,878 - 47,878 (19,030 )


RECONCILIATION OF FUNDS
Total funds brought forward 125,001 22,377 147,378 166,408

TOTAL FUNDS CARRIED FORWARD 172,879 22,377 195,256 147,378

CONTINUING OPERATIONS
All income and expenditure has arisen from continuing activities.

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER (REGISTERED NUMBER: 05017662)

Balance Sheet
31 DECEMBER 2023

2023 2022
Unrestricted Restricted Total Total
funds funds funds funds
Notes £    £    £    £   
FIXED ASSETS
Investments 12 1 - 1 1

CURRENT ASSETS
Debtors: amounts falling due within one year 13 40,753 - 40,753 17,893
Cash at bank 238,833 22,377 261,210 206,737
279,586 22,377 301,963 224,630

CREDITORS
Amounts falling due within one year 14 (69,926 ) - (69,926 ) (45,129 )

NET CURRENT ASSETS 209,660 22,377 232,037 179,501

TOTAL ASSETS LESS CURRENT LIABILITIES 209,661 22,377 232,038 179,502

CREDITORS
Amounts falling due after more than one year 15 (36,782 ) - (36,782 ) (32,124 )

NET ASSETS 172,879 22,377 195,256 147,378
FUNDS 16
Unrestricted funds:
General fund 172,879 125,001
Restricted funds:
BASL nurses fund 6,627 6,627
CCA UK Neil Blenkinsop donation for research
only
15,750 15,750
22,377 22,377
TOTAL FUNDS 195,256 147,378

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.


The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.



THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER (REGISTERED NUMBER: 05017662)

Balance Sheet - continued
31 DECEMBER 2023

The trustees acknowledge their responsibilities for
(a)ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.


The financial statements were approved by the Board of Trustees and authorised for issue on 19 September 2024 and were signed on its behalf by:





Dr A M Elsharkawy - Trustee

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Cash Flow Statement
for the year ended 31 DECEMBER 2023

2023 2022
Notes £    £   

Cash flows from operating activities
Cash generated from operations 1 50,366 (5,449 )
Net cash provided by/(used in) operating activities 50,366 (5,449 )

Cash flows from investing activities
Interest received 4,107 828
Net cash provided by investing activities 4,107 828

Change in cash and cash equivalents in the
reporting period

54,473

(4,621

)
Cash and cash equivalents at the beginning of
the reporting period

206,737

211,358
Cash and cash equivalents at the end of the
reporting period

261,210

206,737

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Notes to the Cash Flow Statement
for the year ended 31 DECEMBER 2023

1. RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASH FLOW FROM OPERATING ACTIVITIES
2023 2022
£    £   
Net income/(expenditure) for the reporting period (as per the Statement of
Financial Activities)

47,878

(19,030

)
Adjustments for:
Interest received (4,107 ) (828 )
Increase in debtors (22,860 ) (3,429 )
Increase in creditors 29,455 17,838
Net cash provided by/(used in) operations 50,366 (5,449 )


2. ANALYSIS OF CHANGES IN NET FUNDS

At 1.1.23 Cash flow At 31.12.23
£    £    £   
Net cash
Cash at bank 206,737 54,473 261,210
206,737 54,473 261,210
Total 206,737 54,473 261,210

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Notes to the Financial Statements
for the year ended 31 DECEMBER 2023

1. ACCOUNTING POLICIES

General information
The charity is a private company limited by guarantee, registered in England and Wales and a registered charity in England and Wales. The address of the registered office is Executive Business Support, Davidson Road, Lichfield, Staffordshire, England, WS14 9DZ.

Basis of preparing the financial statements
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value.

The presentational currency of BASL is considered to be pounds sterling and the financial statements are rounded to the nearest pound.

Incoming resources
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Income received for a specific restricted purpose is credited to a separate restricted fund which is shown in a note to the financial statements. Total incoming resources credited to restricted funds are disclosed on the statement of financial activities which also shows incoming resources in respect of unrestricted funds.

Conference income represents fees and sponsorship received in respect of conference's organised in pursuit of the company's charitable objectives.

Income associated with conferences of future accounting periods is treated as deferred income.

Resources expended
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. Resources expended are included in the statement of financial activities on an accrual basis exclusive of VAT.
All irrecoverable VAT is charged against the category of resources expended for which it was incurred.

Taxation
The activities of the charity are exempt from Corporation Tax under Section 505 of the Income and Corporation Taxes Act 1988 to the extent that they are applied to the organisation's charitable objects.

Fund accounting
Unrestricted funds are donations and other incoming resources received or generated for the general charitable purposes of the charity.
Within unrestricted funds are designated funds. The nature of each of the designated funds is referred to within the report of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.


THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2023

1. ACCOUNTING POLICIES - continued

Debtors and creditors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

Cash and cash equivalents
Cash and cash equivalents include cash in hand and deposits held at call with banks.

2. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In preparing the financial statements it is necessary to make certain judgements, estimates and assumptions that affect the amounts recognised int he financial statements.

In the view of the trustees in applying the accounting policies adopted, no judgements were required that have a significant effect on the amounts recognised in the financial statements nor do any estimates or assumptions made carry a significant risk of material adjustment in the next financial year.

3. MEMBERSHIP SUBSCRIPTIONS
2023 2022
£    £   
Grants 12,729 -
Subscriptions 103,654 99,160
116,383 99,160

Grants receivable are credited to the Statement of Financial Activities (SOFA) in the year for the year for which they are received. Deferred income represents amounts received for future periods an dis released to incoming resources in the period for which it has been received.

4. CONFERENCE FEES & SPONSORSHIP INCOME
2023 2022
£    £   
Conference income 413,049 297,904


THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2023

5. INTEREST RECEIVABLE
2023 2022
£    £   
Interest receivable 4,107 828

6. DIRECT CONFERENCE COSTS
2023 2022
£    £   
Annual conference costs 274,284 194,548
Annual support to UKLA 13,250 11,500
287,534 206,048

7. OTHER ASSOCIATED CONFERENCE COSTS
2023 2022
£    £   
Travel & hotels 12,511 2,242
Artwork/design & print 4,216 3,536
CPD application 956 284
Bank charges 5,282 4,196
Website 4,408 6,185
Secretarial support costs 8,044 5,751
EBS Costs 170,635 175,204
Partial exemption input VAT (16,939 ) -
189,113 197,398

8. SUPPORT COSTS
Governance
costs
£   
Other resources expended 9,014

9. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

2023 2022
£    £   
Accountancy fees 5,012 5,047


THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2023

10. TRUSTEES' REMUNERATION AND BENEFITS

No trustees received any remuneration during the current or prior year.

Trustees' expenses

Travel and speaker expenses totalling £525.36 (2022; £728.30) were reimbursed to 4 (2022; 4) trustees during the year.

11. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES
Unrestricted Restricted Total
funds funds funds
£    £    £   
INCOME AND ENDOWMENTS FROM
Membership subscriptions 99,160 - 99,160

Conference fees & sponsorship income 297,904 - 297,904
Interest receivable 828 - 828
Total 397,892 - 397,892

EXPENDITURE ON
Conference costs
Direct conference costs 206,048 - 206,048
Other associated conference costs 197,398 - 197,398
403,446 - 403,446


Other 13,476 - 13,476
Total 416,922 - 416,922

NET INCOME/(EXPENDITURE) (19,030 ) - (19,030 )


RECONCILIATION OF FUNDS
Total funds brought forward 144,031 22,377 166,408

TOTAL FUNDS CARRIED FORWARD 125,001 22,377 147,378


THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2023

12. FIXED ASSET INVESTMENTS
Unlisted
investments
£   
MARKET VALUE
At 1 January 2023 and 31 December 2023 1
NET BOOK VALUE
At 31 December 2023 1
At 31 December 2022 1

There were no investment assets outside the UK.

13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors 32,418 17,500
Prepayments 8,335 393
40,753 17,893

14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Deferred income

20232022
£   £   
Deferred income at 1 January 202223,00014,000
Resources deferred during the year23,78023,000
Amounts released from prior year(23,000(14,000)
Deferred income at 31 December 202223,78023,000

Deferred income relates to income received in the year specifically relating to performance conditions to be met in the following year.


THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2023

15. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2023 2022
£    £   
Bursary Fund - support for members to attend meetings 24,303 20,381
Swansea health economics work to accompany HCCUK Projec - (736 )
BLNA restricted fund 12,479 12,479
36,782 32,124

16. MOVEMENT IN FUNDS
Net
movement At
At 1.1.23 in funds 31.12.23
£    £    £   
Unrestricted funds
General fund 125,001 47,878 172,879

Restricted funds
BASL nurses fund 6,627 - 6,627
CCA UK Neil Blenkinsop donation for
research only

15,750

-

15,750
22,377 - 22,377
TOTAL FUNDS 147,378 47,878 195,256

Net movement in funds, included in the above are as follows:

Incoming Resources Movement
resources expended in funds
£    £    £   
Unrestricted funds
General fund 533,539 (485,661 ) 47,878

TOTAL FUNDS 533,539 (485,661 ) 47,878


THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2023

16. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

Net
movement At
At 1.1.22 in funds 31.12.22
£    £    £   
Unrestricted funds
General fund 144,031 (19,030 ) 125,001

Restricted funds
BASL nurses fund 6,627 - 6,627
CCA UK Neil Blenkinsop donation for
research only

15,750

-

15,750
22,377 - 22,377
TOTAL FUNDS 166,408 (19,030 ) 147,378

Comparative net movement in funds, included in the above are as follows:

Incoming Resources Movement
resources expended in funds
£    £    £   
Unrestricted funds
General fund 397,892 (416,922 ) (19,030 )

TOTAL FUNDS 397,892 (416,922 ) (19,030 )

17. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2023.